Norway · Delayed Price · Currency is NOK Lifecare ASA Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 marked a transformative quarter with key milestones in implant validation, regulatory progress, and operational restructuring. Significant cost reductions and capital raises improved financial stability, while the focus shifts to regulatory execution and scaling production.
Fiscal Year 2025
-
Q4 2025 marked a shift from technology validation to operational execution, with regulatory milestones achieved and manufacturing reproducibility confirmed. Financially, short-term funding is secured, but future progress depends on warrant uptake and additional capital.
-
Secured $80M in funding and finalized CGM product design, with veterinary launch expected in H1 2026 and human CE mark targeted for 2027. Q3 saw high operating expenses due to product development, with cash runway into Q2 2026.
-
Development of implantable CGMs advanced with design freeze, clinical trial prep, and strategic partnerships. Q2 saw stable expenses, NOK 32M cash, and NOK 16M raised. Human and veterinary launches targeted for 2027 and 2025, with additional financing planned.
-
Advanced toward commercialization with design freeze and manufacturability on track, improved sensor chemistry, and a clear focus on the human and veterinary diabetes markets. Q1 saw NOK 25M in operating expenses and a NOK 25M loss, with a strong cash position and funding runway into 2026.
Fiscal Year 2024
-
Achieved Euronext Oslo Børs listing and advanced product development with improved sensor chemistry and implant miniaturization. Q4 OpEx was NOK 34 million, with costs expected to decrease in 2025. Best case for CE mark is 2026, with veterinary market entry planned for 2025.
-
Uplisting, automation advances, and a successful dog study marked the quarter, while the veterinary product launch was postponed to 2025 to ensure quality. Financials were stable, and strategic partnerships and acquisitions strengthened the foundation for future growth.